Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Mounjaro is clinically proven to support blood sugar control and weight loss, but it may also influence mood in some users. A daily depression checklist can help you identify common emotional shifts, subtle mood changes, and early warning signs. Review the full checklist below to understand the key questions and factors to consider.
Persistent or worsening symptoms—such as suicidal thoughts, hopelessness, or impaired daily functioning—are serious red flags that require prompt medical attention. See below for a complete list of warning signs, risk factors, and recommended next steps.
Because mood changes can be subtle and easy to overlook, taking a free, instant, online symptom check is one of the fastest ways to clarify what you're experiencing. In just a few minutes, you'll get personalized insights based on your symptoms, helping you decide whether to monitor at home, adjust your care plan, or speak with a doctor right away. Don't guess—get clarity now.
Reviewed for medical accuracy: 07/09/2026
Mounjaro (tirzepatide) has proven benefits for blood sugar control and weight loss, but some users report mood changes after starting the medication. If you're asking, "Mounjaro depression after starting—should I be worried?" this checklist will help you sort through common experiences, warning signs and next steps.
Mounjaro is a once-weekly injectable medication approved for type 2 diabetes and, more recently, for chronic weight management. It activates two gut hormone receptors (GLP-1 and GIP), which
These effects can lead to significant weight loss and better glycemic control, but any change in metabolism or appetite can also influence mood.
Clinical trials and real-world data show the most frequent side effects are gastrointestinal and tend to improve over time:
Mood changes or depressive symptoms weren't among the top reported side effects in trials, but as Mounjaro use grows, post-marketing reports are emerging.
Some patients describe feeling low, irritable or anxious after starting Mounjaro. Possible explanations include:
Currently, there's no definitive proof that tirzepatide directly causes depression. However, it's wise to monitor mood closely, especially during the first few weeks.
Track your mood daily for at least two weeks. Use this checklist to flag possible depression:
If you answer "yes" to several questions, it's time to take action.
Not all sadness or stress counts as clinical depression. Watch for these alarm signals:
Any sign of self-harm or suicidal ideation is an emergency. Call emergency services or go to your nearest hospital.
Certain factors make you more vulnerable to mood disorders on any new medication:
If you have one or more risk factors, discuss closer mood monitoring with your doctor before and after starting Mounjaro.
While researching "Mounjaro depression after starting," consider these practical steps:
Small lifestyle tweaks may ease low-mood symptoms as your body adjusts.
If you're experiencing mood changes and want to better understand what you're going through, you can check your symptoms with Ubie's free AI-powered tool in just 3 minutes to receive personalized guidance and help determine whether professional support may be needed.
So far, large tirzepatide trials haven't flagged depression as a common side effect. Key points from peer-reviewed studies:
However, trial populations may differ from real‐world patients, and long-term mood effects are still under study.
Any serious or persistent symptom deserves medical attention. Contact your healthcare provider if you experience:
Never hesitate to reach out—early intervention can prevent complications.
Mounjaro offers powerful benefits for diabetes and weight loss, but it's wise to monitor your mood closely after starting.
Always speak to a doctor about anything serious or potentially life-threatening.
(References)
* Iasevoli F, Ammirati F, Mungo S, Corbi G, Cirillo P, Di Maro M, Iasevoli M. The Impact of GLP-1 Receptor Agonists on Mood and Anxiety Disorders: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Mar 25;11(7):1777. doi: 10.3390/jcm11071777. PMID: 35467479.
* Han M, Li B, Zhang M. GLP-1 receptor agonists for obesity: effects on mental health. J Psychiatr Res. 2023 Jul;163:155-161. doi: 10.1016/j.jpsychires.2023.05.013. Epub 2023 May 16. PMID: 37375685.
* Gadde KM, Khuri S, Khuri T. Antiobesity Medications: A Systematic Review of Psychiatric Adverse Events. Obes Facts. 2022;15(4):612-623. doi: 10.1159/000525287. Epub 2022 Jul 18. PMID: 35849845.
* Moussa M, Charara R, Abi-Hanna D, Zalaket K, Rizk J. The impact of bariatric surgery and medical weight loss on mental health: A systematic review and meta-analysis. Obes Rev. 2023 Nov;24(11):e13636. doi: 10.1111/obr.13636. Epub 2023 Sep 13. PMID: 37701768.
* Wang Y, Zhao R, Gao C. GLP-1 Receptor Agonists and Their Potential as Novel Therapeutics for Depression and Anxiety. Pharmaceuticals (Basel). 2023 May 23;16(6):783. doi: 10.3390/ph16060783. PMID: 37243301.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.